Inflammatory Targets for Preventing Atherothrombotic Events: An Update

Author(s): Federico Carbone, Fabrizio Montecucco.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 29 , 2019

[1]
Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114(12): 1867-79.
[2]
Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis. Int Heart J 2016; 57(2): 134-9.
[3]
Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35(27): 1782-91.
[4]
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[5]
Liberale L, Camici GG. The role of vascular aging in atherosclerotic plaque development and vulnerability. Curr Pharm Des 2019; 25(29): 3098-111.
[6]
Vecchié A, Montecucco F, Carbone F, Dallegri F, Bonaventura A. Diabetes and vascular disease: Is it all about glycemia? Curr Pharm Des 2019; 25(29): 3112-27.
[7]
Satta N, Frias MA, Vuilleumier N, Pagano S. Humoral immunity against HDL particle: A new perspective in cardiovascular diseases? Curr Pharm Des 2019; 25(29): 3128-46.
[8]
Piscitelli F, Silvestri C. Role of the endocannabinoidome in human and mouse atherosclerosis. Curr Pharm Des 2019; 25(29): 3147-64.
[9]
Taghizadeh E, Taheri F, Renani PG, Reiner Ž, Navashenaq JG, Sahebkar A. Macrophage: A key therapeutic target in atherosclerosis? Curr Pharm Des 2019; 25(29): 3165-74.
[10]
Veloso CD, Belew GD, Ferreira LL, et al. A mitochondrial approach to cardiovascular risk and disease. Curr Pharm Des 2019; 25(29): 3175-95.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 25
ISSUE: 29
Year: 2019
Page: [3097 - 3097]
Pages: 1
DOI: 10.2174/138161282529191007154601

Article Metrics

PDF: 22
HTML: 4
PRC: 1